A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease-Reference-Cited by-同舟云学术

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease

Published:2007-02 Issue:3 Volume:136 Page:501-508
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Vichinsky Elliott,Onyekwere Onyinye,Porter John,Swerdlow Paul,Eckman James,Lane Peter,Files Beatrice,Hassell Kathryn,Kelly Patrick,Wilson Felicia,Bernaudin Françoise,Forni Gian Luca,Okpala Iheanyi,Ressayre-Djaffer Catherine,Alberti Daniele,Holland Jaymes,Marks Peter,Fung Ellen,Fischer Roland,Mueller Brigitta U.,Coates Thomas,

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2006.06455.x/fullpdf

Reference23 articles.

1. Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler Ultrasonography

2. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease

3. Magnetic-Susceptibility Measurement of Human Iron Stores

4. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major

5. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

Cited by 242 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring triazole-based drugs: Synthesis, application, FDA approvals, and clinical trial updates–A comprehensive review;Tetrahedron;2024-08

2. Managing gastrointestinal challenges: Diarrhea in sickle cell anemia;Medicine;2024-05-03

3. Role of CENPF and NDC80 in the rehabilitation nursing of hepatocellular carcinoma and cirrhosis: An observational study;Medicine;2024-05-03

4. Application of Deferoxamine in Tissue Regeneration Attributed to Promoted Angiogenesis;Molecules;2024-04-29

5. Compare the Efficacy and Safety of Deferoxamine, Deferasirox, and Deferiprone in Patients With Sickle Cell Disease or Transfusion-Dependent Anemia: A Network Meta-Analysis of Randomized Control Trials;Cureus;2024-02-05